MY205672A - Anti-phf-tau antibodies and uses thereof - Google Patents
Anti-phf-tau antibodies and uses thereofInfo
- Publication number
- MY205672A MY205672A MYPI2019005282A MYPI2019005282A MY205672A MY 205672 A MY205672 A MY 205672A MY PI2019005282 A MYPI2019005282 A MY PI2019005282A MY PI2019005282 A MYPI2019005282 A MY PI2019005282A MY 205672 A MY205672 A MY 205672A
- Authority
- MY
- Malaysia
- Prior art keywords
- antibodies
- phf
- tau antibodies
- tau
- tauopathies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472214P | 2017-03-16 | 2017-03-16 | |
| PCT/US2018/022782 WO2018170351A1 (en) | 2017-03-16 | 2018-03-16 | Anti-phf-tau antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY205672A true MY205672A (en) | 2024-11-05 |
Family
ID=63521020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019005282A MY205672A (en) | 2017-03-16 | 2018-03-16 | Anti-phf-tau antibodies and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10766953B2 (enExample) |
| EP (1) | EP3596119A4 (enExample) |
| JP (3) | JP7159185B2 (enExample) |
| KR (2) | KR102695287B1 (enExample) |
| CN (2) | CN117209599A (enExample) |
| AR (1) | AR111288A1 (enExample) |
| AU (1) | AU2018234709B2 (enExample) |
| CA (1) | CA3055598A1 (enExample) |
| CL (1) | CL2019002566A1 (enExample) |
| EA (1) | EA201992038A1 (enExample) |
| IL (2) | IL268700B2 (enExample) |
| JO (1) | JOP20180021A1 (enExample) |
| MA (1) | MA47789A (enExample) |
| MX (2) | MX2019010922A (enExample) |
| MY (1) | MY205672A (enExample) |
| PH (1) | PH12019501973A1 (enExample) |
| SG (1) | SG11201907754RA (enExample) |
| TW (1) | TWI771389B (enExample) |
| UA (1) | UA128385C2 (enExample) |
| UY (2) | UY37635A (enExample) |
| WO (1) | WO2018170351A1 (enExample) |
| ZA (2) | ZA202101318B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA114902C2 (uk) * | 2011-12-20 | 2017-08-28 | Янссен Байотек, Інк. | Виділене антитіло, яке зв'язує парний спіральний філамент-тау (псф-тау), та фармацевтична композиція, що містить таке антитіло |
| CN105121465B (zh) | 2013-03-13 | 2020-09-08 | 普罗塞纳生物科技公司 | Tau免疫疗法 |
| IL262726B2 (en) | 2016-05-02 | 2024-07-01 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| FI3452507T3 (fi) | 2016-05-02 | 2022-12-15 | Tau-immuunihoito | |
| CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
| IL270375B2 (en) | 2017-05-02 | 2024-12-01 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| TWI853617B (zh) | 2017-10-16 | 2024-08-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| US12234280B2 (en) | 2018-03-05 | 2025-02-25 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| KR20210134943A (ko) | 2019-03-03 | 2021-11-11 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| JP7291250B2 (ja) * | 2019-05-31 | 2023-06-14 | イーライ リリー アンド カンパニー | ヒトタウを標的とする化合物および方法 |
| CA3148740A1 (en) * | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| JP2023521763A (ja) * | 2020-04-08 | 2023-05-25 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｐｈｆ－タウ抗体及びその使用 |
| PH12023550065A1 (en) * | 2020-07-14 | 2024-03-18 | Janssen Pharmaceutica Nv | Blood-based assay for detecting tauopathy or amyloidogenic disease |
| CA3199806A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Methods of reducing tau in human subjects |
| WO2022090169A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Method of safe administration of anti-tau antibody |
| CN116635414A (zh) * | 2021-02-19 | 2023-08-22 | 卫材R&D管理有限公司 | 抗pt217 tau抗体 |
| AU2022242135A1 (en) | 2021-03-26 | 2023-11-09 | Janssen Biotech, Inc. | Anti-tau antibodies and uses thereof |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| JP2025535203A (ja) | 2022-09-15 | 2025-10-23 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| CN116948024B (zh) * | 2023-09-14 | 2024-02-06 | 北京凯祥弘康生物科技有限公司 | 抗Tau蛋白的捕获抗体 |
| CN116948023B (zh) * | 2023-09-14 | 2024-02-09 | 北京凯祥弘康生物科技有限公司 | Tau蛋白抗体及其应用 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| JP3909084B2 (ja) | 1991-10-25 | 2007-04-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 微小管結合タンパク質タウに対するモノクローナル抗体 |
| WO1995017429A1 (en) * | 1993-12-21 | 1995-06-29 | Innogenetics N.V. | Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications |
| AU710952B2 (en) | 1994-07-29 | 1999-09-30 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| CA2509136C (en) | 2003-01-24 | 2013-10-29 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| EP1720908A2 (en) | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| MX2009001341A (es) | 2006-08-04 | 2009-05-28 | Novartis Ag | Anticuerpos especificos de ephb3 y usos de los mismos. |
| JP2010235447A (ja) | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| CA2742968C (en) * | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| JP5917394B2 (ja) | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | 病理学的タウタンパク質の免疫学的標的化方法 |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US8912355B2 (en) | 2009-09-29 | 2014-12-16 | University Of Ottawa Heart Institute | Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
| EP2488867B1 (en) | 2009-10-14 | 2020-09-30 | Janssen Biotech, Inc. | Methods of affinity maturing antibodies |
| US8481687B2 (en) | 2010-04-09 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
| US9304138B2 (en) | 2010-10-07 | 2016-04-05 | Katholieke Universiteit Leuven | Pharmaceutical composition |
| PT2627672T (pt) | 2010-10-11 | 2018-11-16 | Univ Zuerich | Anticorpos anti-tau humanos |
| UA114902C2 (uk) * | 2011-12-20 | 2017-08-28 | Янссен Байотек, Інк. | Виділене антитіло, яке зв'язує парний спіральний філамент-тау (псф-тау), та фармацевтична композиція, що містить таке антитіло |
-
2017
- 2017-03-16 JO JOP/2018/0021A patent/JOP20180021A1/ar unknown
-
2018
- 2018-03-15 TW TW107108890A patent/TWI771389B/zh active
- 2018-03-16 MY MYPI2019005282A patent/MY205672A/en unknown
- 2018-03-16 IL IL268700A patent/IL268700B2/en unknown
- 2018-03-16 WO PCT/US2018/022782 patent/WO2018170351A1/en not_active Ceased
- 2018-03-16 SG SG11201907754RA patent/SG11201907754RA/en unknown
- 2018-03-16 AU AU2018234709A patent/AU2018234709B2/en active Active
- 2018-03-16 MA MA047789A patent/MA47789A/fr unknown
- 2018-03-16 KR KR1020237037321A patent/KR102695287B1/ko active Active
- 2018-03-16 EA EA201992038A patent/EA201992038A1/ru unknown
- 2018-03-16 IL IL310464A patent/IL310464A/en unknown
- 2018-03-16 JP JP2019549574A patent/JP7159185B2/ja active Active
- 2018-03-16 CA CA3055598A patent/CA3055598A1/en active Pending
- 2018-03-16 CN CN202310854848.XA patent/CN117209599A/zh active Pending
- 2018-03-16 MX MX2019010922A patent/MX2019010922A/es unknown
- 2018-03-16 AR ARP180100620A patent/AR111288A1/es unknown
- 2018-03-16 KR KR1020197028728A patent/KR102597462B1/ko active Active
- 2018-03-16 UA UAA201910307A patent/UA128385C2/uk unknown
- 2018-03-16 UY UY0001037635A patent/UY37635A/es not_active Application Discontinuation
- 2018-03-16 US US15/923,011 patent/US10766953B2/en active Active
- 2018-03-16 CN CN201880018431.7A patent/CN110799531B/zh active Active
- 2018-03-16 EP EP18767083.1A patent/EP3596119A4/en active Pending
-
2019
- 2019-08-28 PH PH12019501973A patent/PH12019501973A1/en unknown
- 2019-09-09 CL CL2019002566A patent/CL2019002566A1/es unknown
- 2019-09-13 MX MX2024015440A patent/MX2024015440A/es unknown
-
2020
- 2020-08-06 US US16/986,615 patent/US11365244B2/en active Active
-
2021
- 2021-02-26 ZA ZA2021/01318A patent/ZA202101318B/en unknown
-
2022
- 2022-05-18 US US17/747,785 patent/US20230047413A1/en active Pending
- 2022-10-12 JP JP2022164041A patent/JP2022191383A/ja not_active Withdrawn
-
2023
- 2023-12-12 ZA ZA2023/11412A patent/ZA202311412B/en unknown
-
2024
- 2024-03-29 JP JP2024055230A patent/JP2024088689A/ja not_active Withdrawn
- 2024-07-19 UY UY0001040829A patent/UY40829A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202311412B (en) | Anti-phf-tau antibodies and uses thereof | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| PH12019501357A1 (en) | Anti-ox40 antibodies and their uses | |
| HK1254880A1 (zh) | 抗pd-1抗体及其应用 | |
| HK1255604A1 (zh) | 抗pd-l1抗体及其用途 | |
| PH12019500540A1 (en) | Anti-pd-1 antibodies and their uses | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| ZA202006318B (en) | Anti-dll3 antibodies and uses thereof | |
| PH12018502456A1 (en) | Anti-cd04 antibodies and their uses | |
| IL268007A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis | |
| MY193821A (en) | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | |
| MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
| PH12022553035A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
| MX2024002238A (es) | Anticuerpos anti-ccr8 y uso de los mismos. | |
| PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
| MX2023011339A (es) | Anticuerpos anti-tau y usos de estos. | |
| EA202092121A1 (ru) | Антитела против cd73 и их применения | |
| HK40018974A (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |